Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
350
Employees350
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
350
Employees350

HALO Key Statistics

Market cap
7.73B
Market cap7.73B
Price-Earnings ratio
13.55
Price-Earnings ratio13.55
Dividend yield
Dividend yield
Average volume
2.85M
Average volume2.85M
High today
$66.39
High today$66.39
Low today
$64.55
Low today$64.55
Open price
$64.85
Open price$64.85
Volume
1.74M
Volume1.74M
52 Week high
$79.50
52 Week high$79.50
52 Week low
$46.26
52 Week low$46.26

Stock Snapshot

The current Halozyme Therapeutics(HALO) stock price is $65.77, with a market capitalization of 7.73B. The stock trades at a price-to-earnings (P/E) ratio of 13.55.

During the trading session on 2025-12-17, Halozyme Therapeutics(HALO) shares reached a daily high of $66.39 and a low of $64.55. At a current price of $65.77, the stock is +1.9% higher than the low and still -0.9% under the high.

Trading volume for Halozyme Therapeutics(HALO) stock has reached 1.74M, versus its average volume of 2.85M.

The stock's 52-week range extends from a low of $46.26 to a high of $79.50.

The stock's 52-week range extends from a low of $46.26 to a high of $79.50.

HALO News

Simply Wall St 4d
Did Patent Win and Jim Lang’s Arrival Just Shift Halozyme Therapeutics’ Investment Narrative?

Earlier this month, Halozyme Therapeutics, Inc. elected veteran healthcare executive Jim Lang to its Board of Directors, adding deep commercialization, data ana...

Did Patent Win and Jim Lang’s Arrival Just Shift Halozyme Therapeutics’ Investment Narrative?

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.